Full-Time

Senior Vice President Head of FP&A

Evotec

Evotec

1,001-5,000 employees

Global drug-discovery services via partnerships

No salary listed

Trafford, UK + 2 more

More locations: Oxford, UK | Hamburg, Germany

In Person

Category
Accounting (2)
,
Required Skills
Forecasting
Requirements
  • University degree in Finance, Accounting, Business, Economics, or a related discipline.
  • Experience managing international finance teams and global planning cycles.
  • Strong command of financial systems, reporting tools, and data modelling best practices.
Responsibilities
  • Act as a key strategic partner to the Chief Financial Officer, and EVP Global FP&A and Controllership, on financial presentations, capital markets communication, and investor engagement.
  • Prepare and manage external presentations and messaging for investors, analysts, and other key stakeholders, including earnings materials, investor days, and board-level briefings.
  • Develop and deliver compelling financial narratives to support market communications, Mergers and Acquisitions activity, and long-term positioning of the Group.
  • Lead the global FP&A function, ensuring strategic alignment, transparency, and value creation across all regions and business units.
  • Drive the annual budget, rolling forecast, and long-range planning process, ensuring integration with business strategy and market outlook.
  • Identify and track key performance indicators to drive business accountability and highlight strategic opportunities or risks.
  • Lead and develop a high-performing team of six, creating a culture of excellence, collaboration, and strategic insight.
  • Coordinate cross-functionally with Finance Business Partnering and Global Business Controlling to deliver consistent and aligned financial support globally.
  • Own and optimize the global financial data model, including internal financial reporting and planning tools for decision-making at all levels.
  • Champion the Tech Strategy within Finance, driving modernization of reporting systems and data infrastructure in support of finance transformation.
Desired Qualifications
  • MBA or advanced degree preferred.
  • Experience in financial strategy, investor relations, or market communications, preferably in pharma, life sciences, or management consulting.
  • Strong background in consulting or corporate strategy, with a proven ability to distill complex financial data into actionable insights and market narratives.
  • Track record of executive-level business partnering, with excellent communication and presentation skills tailored to internal and external audiences.
  • Experience managing international finance teams and global planning cycles.
  • Ability to distill complex financial data into actionable insights and market narratives.
  • Excellent English communication skills; additional languages are a plus.
  • Truly international mindset, with experience working in multinational and cross-cultural environments.

Evotec provides R&D services for drug discovery and development through strategic partnerships with pharma, biotech, and academic institutions, using platforms like iPSCs and machine learning. It conducts experiments and data analysis with iPSC-derived cellular models and AI/ML tools to identify and optimize drug candidates, often incorporating patient-derived materials for precision medicine, offering end-to-end discovery through clinical development under contract. The company differentiates itself with an integrated, data-driven, cell-based platform within a collaboration model and a focus on precision medicine, biologics, and gene therapy, with a strong US and European presence. Its goal is to bring new and better medicines to patients faster and at lower cost by making drug discovery and development more efficient through partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hamburg, Germany

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Rui Wang's 2026 AI appointment strengthens data-driven discovery commercialization.[1]
  • J.Train's Sandoz-validated launch opens near-term biologics manufacturing revenue.[3]
  • Horizon targets €75 million structural savings by end-2027, supporting margin recovery.[1]

What critics are saying

  • Discovery demand remains weak, driving Q1 2026 revenue down 21.7%.[1]
  • Revenue depends heavily on large milestone and license payments from partners.[1]
  • Horizon execution risks persist amid site closures, 800 layoffs, and reorganization costs.[1]

What makes Evotec unique

  • Evotec combines drug discovery, iPSC disease modeling, and AI-driven workflows.[1][2]
  • Just–Evotec Biologics adds continuous manufacturing and CDMO capabilities to the platform.[3]
  • The company serves Top 20 pharma, 800-plus biotechs, and academic partners.[1]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Evotec who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 8th, 2026
Evotec delivers $67M cost savings and $650M Sandoz deal amid 1.1% revenue decline

Evotec SE reported mixed Q4 2025 results, with group revenue increasing 14.5% to €253.3 million, though full-year revenue fell 1.1% to €788.4 million. Adjusted group EBITDA for Q4 rose 103.6% to €58 million, whilst full-year EBITDA increased 81.9% to €41.1 million. The Just-Evotec Biologics segment achieved breakthrough growth, with Q4 revenue surging 104.2% and full-year revenue rising 39.8% to €259.4 million. The company secured a $650 million agreement with Sandoz and received multiple milestone payments from partnerships. Evotec delivered over €60 million in annualised cost savings and reduced capital expenditure by approximately 60%. The company is implementing its Horizon transformation programme, expected to deliver €75 million in structural savings by end-2027, though this involves closing four sites and eliminating 800 positions.

The Associated Press
Apr 7th, 2026
Evotec nominates Dieter Weinand as supervisory board chairman to drive commercial execution

Evotec has nominated Dieter Weinand as chairman of its supervisory board, pending approval at the 11 June 2026 annual general meeting. Weinand will succeed Prof. Dr Iris Löw-Friedrich, whose term concludes at the meeting as part of the company's planned succession process. Weinand brings over 30 years of pharmaceutical industry experience, having served as president, CEO and chairman of Bayer Pharmaceuticals and held senior roles at Pfizer, Bristol Myers Squibb and Sanofi. He currently serves on several biotech boards and will reduce his board commitments to comply with German corporate governance requirements. The appointment aims to strengthen Evotec's commercial execution, strategic partnerships and profitability as the Hamburg-based life sciences company continues its transformation. Weinand holds an MS in pharmacology and toxicology from Long Island University.

The Associated Press
Apr 1st, 2026
Evotec appoints Dr. Ashiq H. Khan as chief commercial officer with $7B+ deal track record

Evotec has appointed Dr Ashiq H Khan as chief commercial officer. Dr Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, having closed more than $7 billion in agreements across US, EU and APAC markets. In his new role, Dr Khan will build a globally integrated commercial organisation aligned with Evotec's scientific capabilities. He most recently served as chief business officer at Iktos and previously held leadership roles at Proteros and Schrödinger. Evotec is a life science company specialising in drug discovery and development, integrating AI-driven innovation with advanced technologies. The company employs over 4,800 experts across Europe and the US.

The Associated Press
Mar 19th, 2026
Evotec receives $10M milestone from Bristol Myers Squibb for kidney cancer drug trial

Evotec has received a $10 million milestone payment from Bristol Myers Squibb following the initiation of a Phase 1 clinical study for BMS-986506, a protein degradation treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer. The study marks the first clinical milestone in the strategic protein degradation partnership between Evotec and Bristol Myers Squibb, which began in 2018 and was expanded in 2022. BMS-986506 is a cereblon E3 ligase modulator, or "molecular glue", developed using Evotec's multi-omics screening platform and AI-supported data analytics. The collaboration combines Evotec's PanOmics and PanHunter platforms with Bristol Myers Squibb's library of CELMoD agents to discover novel molecular glue degraders for oncology and other therapeutic areas.

Yahoo Finance
Mar 16th, 2026
Evotec unveils "Horizon" plan with $85M savings, 800 job cuts and 10-site footprint by 2028

Evotec has unveiled "Horizon", a transformation plan targeting €75 million in savings and guiding 2026 EBITDA to €0–40 million. The plan focuses on operational excellence, scientific leadership and commercial execution, building on earlier restructuring that delivered over €60 million in savings through end-2025. The company will reduce its global footprint from 14 sites to 10 over two years, resulting in approximately 800 position reductions. Evotec emphasises owned technology hubs in Toulouse and Verona as integrated discovery and preclinical development centres. Chief executive Christian Wojczewski said Evotec has upgraded commercial leadership and business development, with prospects increasing during the second half of 2025. The company previously streamlined its asset pipeline by 30% and reduced capital expenditure by 60% whilst strengthening its balance sheet.